These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 33464021)

  • 21. Pharmacokinetics of pediatric lopinavir/ritonavir tablets in children when administered twice daily according to FDA weight bands.
    Bastiaans DE; Forcat S; Lyall H; Cressey TR; Hansudewechakul R; Kanjanavanit S; Noguera-Julian A; Königs C; Inshaw JR; Chalermpantmetagul S; Saïdi Y; Compagnucci A; Harper LM; Giaquinto C; Colbers AP; Burger DM;
    Pediatr Infect Dis J; 2014 Mar; 33(3):301-5. PubMed ID: 24356253
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Population Pharmacokinetics of Lopinavir/Ritonavir: Changes Across Formulations and Human Development From Infancy Through Adulthood.
    Yang J; Nikanjam M; Best BM; Pinto J; Chadwick EG; Daar ES; Havens PL; Rakhmanina N; Capparelli EV
    J Clin Pharmacol; 2018 Dec; 58(12):1604-1617. PubMed ID: 30252146
    [TBL] [Abstract][Full Text] [Related]  

  • 23. First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir.
    van Vonderen MG; Lips P; van Agtmael MA; Hassink EA; Brinkman K; Geerlings SE; Sutinen J; Ristola M; Danner SA; Reiss P
    AIDS; 2009 Jul; 23(11):1367-76. PubMed ID: 19424051
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Population pharmacokinetics of lopinavir in combination with rifampicin-based antitubercular treatment in HIV-infected South African children.
    Elsherbiny D; Ren Y; McIlleron H; Maartens G; Simonsson US
    Eur J Clin Pharmacol; 2010 Oct; 66(10):1017-23. PubMed ID: 20552180
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic levels of lopinavir in late pregnancy and abacavir passage into breast milk in the Mma Bana Study, Botswana.
    Shapiro RL; Rossi S; Ogwu A; Moss M; Leidner J; Moffat C; Lockman S; Moyo S; Makhema J; Essex M; Capparelli E
    Antivir Ther; 2013; 18(4):585-90. PubMed ID: 23183881
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Birth Outcomes for Pregnant Women with HIV Using Tenofovir-Emtricitabine.
    Rough K; Seage GR; Williams PL; Hernandez-Diaz S; Huo Y; Chadwick EG; Currier JS; Hoffman RM; Barr E; Shapiro DE; Patel K;
    N Engl J Med; 2018 Apr; 378(17):1593-1603. PubMed ID: 29694825
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Steady-state pharmacokinetics of lopinavir plus ritonavir when administered under different meal conditions in HIV-infected Ugandan adults.
    Lamorde M; Byakika-Kibwika P; Boffito M; Nabukeera L; Mayito J; Ogwal-Okeng J; Tjia J; Back D; Khoo S; Ryan M; Merry C
    J Acquir Immune Defic Syndr; 2012 Jul; 60(3):295-8. PubMed ID: 22481601
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Insulin sensitivity in multiple pathways is differently affected during zidovudine/lamivudine-containing compared with NRTI-sparing combination antiretroviral therapy.
    van Vonderen MG; Blümer RM; Hassink EA; Sutinen J; Ackermans MT; van Agtmael MA; Yki-Jarvinen H; Danner SA; Serlie MJ; Sauerwein HP; Reiss P
    J Acquir Immune Defic Syndr; 2010 Feb; 53(2):186-93. PubMed ID: 19898246
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Are Prophylactic and Therapeutic Target Concentrations Different?: the Case of Lopinavir-Ritonavir or Lamivudine Administered to Infants for Prevention of Mother-to-Child HIV-1 Transmission during Breastfeeding.
    Foissac F; Blume J; Tréluyer JM; Tylleskär T; Kankasa C; Meda N; Tumwine JK; Singata-Madliki M; Harper K; Illamola SM; Bouazza N; Nagot N; Van de Perre P; Blanche S; Hirt D
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27895016
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children.
    van der Lee M; Verweel G; de Groot R; Burger D
    Antivir Ther; 2006; 11(4):439-45. PubMed ID: 16856617
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Choice of antiretroviral drugs for postexposure prophylaxis for children: a systematic review.
    Penazzato M; Dominguez K; Cotton M; Barlow-Mosha L; Ford N
    Clin Infect Dis; 2015 Jun; 60 Suppl 3():S177-81. PubMed ID: 25972500
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical experience of raltegravir with abacavir/lamivudine or zidovudine/lamivudine in HIV-infected Korean adults.
    Kang SJ; An JH; Kim J; Jang MO; Kim SE; Park KH; Jung SI; Jang HC
    Jpn J Infect Dis; 2013; 66(4):317-9. PubMed ID: 23883843
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized, double-blind study of triple nucleoside therapy of abacavir, lamivudine, and zidovudine versus lamivudine and zidovudine in previously treated human immunodeficiency virus type 1-infected children. The CNAA3006 Study Team.
    Sáez-Llorens X; Nelson RP; Emmanuel P; Wiznia A; Mitchell C; Church JA; Sleasman J; Van Dyke R; Richardson CG; Cutrell A; Spreen W; Hetherington S
    Pediatrics; 2001 Jan; 107(1):E4. PubMed ID: 11134468
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Population Pharmacokinetics of Lopinavir in Severely Malnourished HIV-infected Children and the Effect on Treatment Outcomes.
    Archary M; Mcllleron H; Bobat R; La Russa P; Sibaya T; Wiesner L; Hennig S
    Pediatr Infect Dis J; 2018 Apr; 37(4):349-355. PubMed ID: 29227461
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Zidovudine/lamivudine for HIV-1 infection contributes to limb fat loss.
    van Vonderen MG; van Agtmael MA; Hassink EA; Milinkovic A; Brinkman K; Geerlings SE; Ristola M; van Eeden A; Danner SA; Reiss P;
    PLoS One; 2009 May; 4(5):e5647. PubMed ID: 19479079
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Population Pharmacokinetics of Pediatric Lopinavir/Ritonavir Oral Pellets in Children Living with HIV in Africa.
    Chupradit S; Wamalwa DC; Maleche-Obimbo E; Kekitiinwa AR; Mwanga-Amumpaire J; Bukusi EA; Nyandiko WM; Mbuthia JK; Swanson A; ; Cressey TR; Punyawudho B; Musiime V;
    Clin Pharmacol Ther; 2024 May; 115(5):1105-1113. PubMed ID: 38247190
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics and 48-week safety and efficacy of generic lopinavir/ritonavir in Thai HIV-infected patients.
    Ramautarsing RA; van der Lugt J; Gorowara M; Sophonphan J; Ananworanich J; Lange JM; Burger DM; Phanuphak P; Ruxthungtham K; Avihingsanon A
    Antivir Ther; 2013; 18(2):249-52. PubMed ID: 22908131
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Zidovudine/lamivudine but not nevirapine in combination with lopinavir/ritonavir decreases subcutaneous adipose tissue mitochondrial DNA.
    Feeney ER; van Vonderen MG; Wit F; Danner SA; van Agtmael MA; Villarroya F; Domingo P; Capeau J; Reiss P; Mallon PW;
    AIDS; 2012 Nov; 26(17):2165-74. PubMed ID: 22874517
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Population pharmacokinetics of lopinavir/ritonavir (Kaletra) in HIV-infected patients.
    López Aspiroz E; Santos Buelga D; Cabrera Figueroa S; López Galera RM; Ribera Pascuet E; Domínguez-Gil Hurlé A; García Sánchez MJ
    Ther Drug Monit; 2011 Oct; 33(5):573-82. PubMed ID: 21912331
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intracellular pharmacokinetics of once versus twice daily zidovudine and lamivudine in adolescents.
    Flynn PM; Rodman J; Lindsey JC; Robbins B; Capparelli E; Knapp KM; Rodriguez JF; McNamara J; Serchuck L; Heckman B; Martinez J;
    Antimicrob Agents Chemother; 2007 Oct; 51(10):3516-22. PubMed ID: 17664328
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.